Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-05-26

Clinical Trial Update: Combining Lesinurad With Allopurinol in Inadequate Responders [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adding lesinurad to allopurinol in gout patients inadequately responding to allopurinol; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Allopurinol (Allopurinol)
  • Zurampic (lesinurad)

Snippet

Sponsor: Ardea Biosciences, Inc. | Conditions: Gout | Phase 3 | Status: COMPLETED | Results posted: 2016-05-26